Coffee break scoop: Sarepta just scored a $100M milestone payment thanks to progress in a rare genetic disorder trial, and retail investors are loving it. The twist? Sarepta sold a chunk of Arrowhead shares to help fund the payout, making both stocks pop. If you’re watching biotech, this is a classic case of how a single clinical trial update can send stocks on a wild ride. Just goes to show, sometimes the biggest moves come from behind-the-scenes deals! #Business #Market #stocks